{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-26-000004","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2026-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.017552+00:00","generated_at":"2026-05-16T01:12:22.093454+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Gossamer Bio Phase 3 PROSERA trial misses primary endpoint, seralutinib shows signals in high-risk PAH","bullets":["Primary 6MWD endpoint missed: +13.3m placebo-adjusted (p=0.0320 vs prespecified α=0.025).","Four key secondary endpoints favored seralutinib; NT-proBNP reduced 120.4 ng/L (p=0.0002).","In intermediate/high-risk (REVEAL Lite 2 ≥6, n=234), 6MWD gain +20.0m (p=0.0207).","Gossamer to meet with FDA to discuss path forward; pauses SERANATA study enrollment.","Seralutinib well tolerated; cough (37%) and transaminase elevations >3x ULN (13%) reported."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-26-000004","json":"https://secwatch.observer/filing/0001728117-26-000004.json","markdown":"https://secwatch.observer/filing/0001728117-26-000004.md","text":"https://secwatch.observer/filing/0001728117-26-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811726000004/0001728117-26-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811726000004/goss-20260223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:12:22.093454+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}